MiR-125b inhibitor may enhance the invasion-prevention activity of Temozolomide in glioblastoma stem cells by targeting pias3

BioDrugs

Volumn 28, Issue 1, 2014, Pages 41-54

  Shi, Lei ^a   Wan, Yi ^b   Sun, Guan ^c   Zhang, Shuguang ^a   Wang, Zhimin ^b   Zeng, Yanjun ^d  

^a JIANGSU UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NANTONG UNIVERSITY   (China)

^d BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; GELATINASE A; GELATINASE B; MESSENGER RNA; MICRORNA 125B; MICRORNA 125B INHIBITOR; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN INHIBITOR OF ACTIVATED STAT3; STAT3 PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ANIMAL CELL; ARTICLE; CANCER STEM CELL; CELL INVASION; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; SEQUENCE ALIGNMENT; TRANSCRIPTION INITIATION; TUMOR INVASION;

ANIMALS; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; DACARBAZINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MICRORNAS; MOLECULAR CHAPERONES; NEOPLASTIC STEM CELLS; PROTEIN INHIBITORS OF ACTIVATED STAT; RNA, SMALL INTERFERING;

EID: 84895762605     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0053-2     Document Type: Article

References (27)

1. Stupp R, Tonn JC, Brada M, et al. High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v190-3.
2. Clarke MJ, Mulligan EA, Grogan PT, et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther. 2009;8:407-14.
3. Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23:2372-7.
4. Mei J, Bachoo R, Zhang C. MicroRNA-146a inhibits glioma development by targeting Notch1. Mol Cell Biol. 2011;31:3584-92.
5. Hatfield SD, Shcherbata HR, Fischer KA, et al. Stem cell division is regulated by the microRNA pathway. Nature. 2005;435:974-8.
6. Shi L, Zhang J, Pan T, et al. MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res. 2010;1312:120-6.
7. Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics. 2009;10:399-416.
8. Rukov JL, Vinther J, Shomron N. Pharmacogenomics genes show varying perceptibility to microRNA regulation. Pharmacogenet Genomics. 2011;21:251-62.
9. Shomron N. MicroRNAs and pharmacogenomics. Pharmacogenomics. 2010;11:629-32.
10. Ren Y, Zhou X, Mei M, et al. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer. 2010;10:27-39.
11. Shi L, Zhang S, Feng K, et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 2012;40(1):119-29.
12. Zhang S, Wan Y, Pan T, et al. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. J Mol Neurosci. 2012;47(2):346-56.
13. Darling JL. The in vitro biology of human brain tumors. In: Thomas DGT, editor. Neuro-oncology: primary malignant brain tumors. Baltimore (MD): Johns Hopkins University Press; 1990: 1-25.
14. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33:e179.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) Method. Methods. 2001;25:402-8.
16. Shi L, Wan Y, Sun G, et al. Functional differences of miR-125b on the invasion of primary glioblastoma CD133-negative cells and CD133-positive cells. Neuromol Med. 2012;14(4):303-16.
17. Xia HF, He TZ, Liu CM, et al. MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem. 2009;23:347-58.
18. Brantley EC, Nabors LB, Gillespie GY, et al. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res. 2008;14:4694-704.
19. Wei D, Le X, Zheng L, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003;22(3):319-29.
20. Pan TH, Wang YY, Zhang SG, et al. Research on the effects of PIAS3 expression on the invasion of glioma TJ905 cells. Zhonghua Wai Ke Za Zhi. 2011;49(5):440-4.
21. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microrna represses cell proliferation pathways in human cells. Cancer Res. 2007;67:7713-22.
22. Wan Y, Fei XF, Wang ZM, et al. Expression of miR-125b in the new, highly invasive glioma stem cell and progenitor cell line SU3. Chin J Cancer. 2012;31(4):207-14.
23. Cairo S, Wang Y, de Reyniès A, et al. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. PNAS. 2010;107:20471-6.
24. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer. 2006;6:425-36.
25. Wang L, Zhang J, Banerjee S, et al. Sumoylation of vimentin354 is associated with PIAS3 inhibition of glioma cell migration. Oncotarget. 2010;1(7):620-7.
26. Zhang X, Sun Y, Pireddu R, et al. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res. 2013;73(6):1922-33.
27. Senft C, Priester M, Polacin M, et al. Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol. 2011;101(3):393-403.